Publications

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Dupont T, Yang SNing, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.  2016.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.. Oncotarget. 7(3):3520-32.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al..  2016.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Purwada A, Jaiswal MK, Ahn H, Nojima T, Kitamura D, Gaharwar AK, Cerchietti L, Singh A.  2015.  Ex vivo engineered immune organoids for controlled germinal center reactions.. Biomaterials. 63:24-34.

Pera B, M Calvo-Vidal N, Ambati S, Jordi M, Kahn A, J Díaz F, Fang W, Altmann K-H, Cerchietti L, Moore MAS.  2015.  High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.. Cancer Lett. 368(1):97-104.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Cerchietti L, Pera B.  2015.  Personalized Epigenetic Therapy - Chemosensitivity Testing. Epigenetic Cancer Therapy. :667-676.

Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, Gomes EMDaGama, Yang C, Patel MR, Shrestha L et al..  2014.  Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.. ACS Chem Biol. 9(8):1698-705.

Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, Gomes EMDaGama, Yang C, Patel MR, Shrestha L et al..  2014.  Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.. ACS Chem Biol. 9(8):1698-705.

Nielsen THolm, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AMarc, Oros KKlein et al..  2014.  Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials.. Cancer Epidemiol Biomarkers Prev. 23(12):2688-93.

Patel RGhanshyam, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A.  2014.  Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications.. Cell Mol Bioeng. 7(3):394-408.

Patel RGhanshyam, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A.  2014.  Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications.. Cell Mol Bioeng. 7(3):394-408.

Irmady K, Jackman KA, Padow VA, Shahani N, Martin LAndres, Cerchietti L, Unsicker K, Iadecola C, Hempstead BL.  2014.  Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury.. J Neurosci. 34(9):3419-28.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.  2014.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.. Breast Cancer Res. 16(6):491.

Zahreddine HAhmad, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E et al..  2014.  The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.. Nature. 511(7507):90-3.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM et al..  2013.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.. Cell Rep. 4(3):578-88.